셀투인은 연구개발 결과를 특허등록, 학술지 게재 및 국제학회 기술 발표를 통해
기술의 우수성과 신뢰성을 입증하고 있습니다.
지적재산권 확보
Cell2in은 글로벌 바이오 시장에서 고유 기술을 활용한 적극적 사업 전개를 위해 국내는 물론 신약개발 주요국가의 고품질 세포치료제 생산기술의 특허를 확보하고 있습니다.
물질 및 용도
Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
---|---|---|---|
세포의 티올수준을 측정하기 위한 실시간 이미징 센서 |
Korea | 10-1862581 | 2018. 05. 24 |
United States | 10.215.757B2 | 2019. 02. 26 | |
Korea | 10-1983803 | 2019. 05. 23 | |
United States | 10.620.215 | 2020. 04. 14 | |
세포의 소기관 내 글루타치온 측정용 실시간 형광 이미징 센서 및 이의 제조방법 |
Korea | 10-2133794 | 2020. 07. 08 |
Canada (application) | 3.072.434 | 2020. 02. 07 | |
Australia (application) | 2018320601 | 2020. 02. 19 | |
United States (application) | 16/640717 | 2020. 02. 20 | |
Europe (application) | 18848372.1 | 2020. 02. 21 | |
China (application) | 201880054675.0 | 2020. 02. 21 | |
India (application) | 202017007994 | 2020. 02. 25 | |
Japan (application) | 2020-511502 | 2020. 02. 19 | |
소포체 내 글루타치온 측정용 실시간 형광 이미지 센서 및 이를 이용하는 방법 |
Korea | 10-2019-0178260 | 2019. 12. 30 |
Gene Biomarker
Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
---|---|---|---|
FreSHtracer 기반 분리된 세포의 유전자 프로파일의 응용 |
PCT | PCT/KR 2018/008239 | 2018. 07. 20 |
Stem Cell Therapy
Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
---|---|---|---|
혈소판 감소증 치료용 조성물 |
Korea | 10-2021-0063975 | 2021. 05. 18 |
고품질의 줄기세포 선별용 마커 및 이를 이용한 고품질 줄기세포 선별 방법 |
Korea | 10-2020-0180455 | 2020. 12. 22 |
Cell Quality Control
Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
---|---|---|---|
실시간 글루타치온 측정을 통한 치료용 세포의 품질 향상 방법 |
Korea | 10-2119714 | 2020. 06. 01 |
Europe (application) | 18883520.1 | 2020. 05. 27 | |
China (application) | 201880077266.2 | 2020. 05. 28 | |
Japan (application) | 2020-546264 | 2020. 05. 27 | |
United States (application) | 16/767985 | 2020. 05. 28 | |
실시간 글루타치온 측정을 통한 치료용 세포의 품질 측정 방법 |
Korea | 10-2145929 | 2020. 08. 12 |
United States (application) | 16/768014 | 2020. 05. 28 | |
Europe (application) | 18884812.1 | 2020. 05. 27 | |
China (application) | 201880077236.1 | 2020. 05. 28 | |
Japan (application) | 2020-546265 | 2020. 05. 27 |
기술 발표 및 게재
셀투인은 국내외 학회와 학술지를 통해 연구 성과를 지속적으로 발표해오고 있습니다.
Development Technology and astrocytes : J. Song et al., Cografting astrocytes improves cell therapeutic outcomes in a Parkinson’s disease model, JCI, 2018, 128(1), 463-482
Transplantation of neural progenitor cells (NPCs) is a potential therapy for treating neurodegenerative disorders, but this
approach has faced many challenges and limited success, primarily because of inhospitable host brain environments that
interfere with enriched neuron engraftment and function. Astrocytes play neurotrophic roles in the developing and adult
brain, making them potential candidates for helping with modification of hostile brain environments. In this study, we
examined whether astrocytic function could be utilized to overcome the current limitations of cell-based therapies in a murine
model of Parkinson’s disease (PD) that is characterized by dopamine (DA) neuron degeneration in the midbrain. We show
here that cografting astrocytes, especially those derived from the midbrain, remarkably enhanced NPC-based cell therapeutic
outcomes along with robust DA neuron engraftment in PD rats for at least 6 months after transplantation. We further show
that engineering of donor astrocytes with Nurr1 and Foxa2, transcription factors that were recently reported to polarize
harmful immunogenic glia into the neuroprotective form, further promoted the neurotrophic actions of grafted astrocytes in
the cell therapeutic approach. Collectively, these findings suggest that cografting astrocytes could be a potential strategy for
successful cell therapeutic outcomes in neurodegenerative disorders.
approach has faced many challenges and limited success, primarily because of inhospitable host brain environments that
interfere with enriched neuron engraftment and function. Astrocytes play neurotrophic roles in the developing and adult
brain, making them potential candidates for helping with modification of hostile brain environments. In this study, we
examined whether astrocytic function could be utilized to overcome the current limitations of cell-based therapies in a murine
model of Parkinson’s disease (PD) that is characterized by dopamine (DA) neuron degeneration in the midbrain. We show
here that cografting astrocytes, especially those derived from the midbrain, remarkably enhanced NPC-based cell therapeutic
outcomes along with robust DA neuron engraftment in PD rats for at least 6 months after transplantation. We further show
that engineering of donor astrocytes with Nurr1 and Foxa2, transcription factors that were recently reported to polarize
harmful immunogenic glia into the neuroprotective form, further promoted the neurotrophic actions of grafted astrocytes in
the cell therapeutic approach. Collectively, these findings suggest that cografting astrocytes could be a potential strategy for
successful cell therapeutic outcomes in neurodegenerative disorders.
학술지 게재
『Stem Cell Report』 | |
『The Journal of Clinical Investigation』 | |
『Science Advances』 |
기술 발표
국제줄기세포학회 기술 발표 |